Eyeworld

139 EW GLAUCOMA April 2016 Contact information Brandt: jdbrandt@ucdavis.edu Sheppard: docshep@hotmail.com timolol drops (TIM group; n=66) for 6 months. Together with safety, diurnal IOP (mm Hg) at weeks 2, 6, and 12, and IOP at months 4, 5, and 6 were considered first-degree and second-degree efficacy measures, respectively. Sustained reduction of IOP was observed through month 6 for both groups. Mean diurnal IOPs at wash- out, weeks 2, 6, and 12, and months 4, 5, and 6 were 23.8, 18.6, 19.2, 19.5, 19.4, 20.2, and 20.1, respec- tively, for the BIM group and 24.1, 18.4, 18.7, 18.3, 18.6, 18.7, and 19.0, respectively, for the TIM group, Dr. Brandt reported. In addition, no unanticipated adverse events were observed. "With a single applied dose, the bimatoprost insert sustained reduction of IOP for 6 months," Dr. Brandt said. "This is a trendsetting and excit- ing development in glaucoma care," said John Sheppard, MD, professor of ophthalmology, microbiology and molecular biology, and clinical direc- tor, Thomas R. Lee Center for Ocular Pharmacology, Eastern Virginia Med- ical School, Norfolk, Virginia. Implant site localization for sustained release medication devices includes: conjunctival cul-de-sac, subconjunctival injection, conjunc- tival surface pellets, scleral implant, periocular or sub-Tenon's injection, transscleral delivery system, su- prachoroidal delivery system, and intravitreal injection, he said. "All key players in this arena are trying to get to the market first, which is a real challenge to the U.S. Food and Drug Administration (FDA)," Dr. Sheppard said. But something will get approved this year, according to Dr. Sheppard. "I think they all have potential but all have unique sets of problems as well," he said. EW References 1. Katz LJ, et al. Twelve-month, random- ized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glauco- ma or ocular hypertension. Am J Ophthalmol. 2010;149:661–671. 2. Li T, et al. Comparative effectiveness of first-line medications for primary open- angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123:129–140. 3. Franca JR, et al. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. PLoS One. 2014;9:e95461. Editors' note: Dr. Brandt has financial interests with ForSight VISION5. Dr. Sheppard has no financial interests related to his comments. www.ziemerusa.com Ziemer's Most Accurate, Gentle, Reliable, Versatile, Cost Effective, and Intuitive device for Refractive and Cataract surgery. Visit us at ASCRS 2016 in booth 2917. The Power of One. Does Everything!? C M Y CM MY CY CMY K 160325_Ziemer_EyeWrld_Ad_V01.pdf 1 3/25/16 1:19 PM

• Cover